← The patent line

Aripiprazole Lauroxil

Sold as ARISTADA, ARISTADA INITIO KIT · given by intramuscular

Ten years or more until it comes off patent
12.6 yr
Until anyone may copy it
Protection runs to 2039-04-06
1
Trials running now
10 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Alkermes Inc
Approval holder
the only company permitted to sell it today
2039-04
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

SchizophreniaPregnant WomenPsychotropic Drugs
03

Who is paying for the research

Alkermes, Inc.
Company
6
Massachusetts General Hospital
University or hospital
1
University of California, Los Ange
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT05662306In routine use2024 · 1 people · stopped early
C-Cog in Early Course Schizophrenia Study

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line